T. Rowe Price Associates
KALV

T. Rowe Price Associates’s KalVista Pharmaceuticals KALV Stock Holding History

T. Rowe Price Associates’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$592K Buy
29,367
+6,249
+27% +$101K ﹤0.01% 2373
2025
Q4 		$374K Buy
23,118
+3,138
+16% +$41.6K ﹤0.01% 2530
2025
Q3 		$244K Buy
19,980
+2,116
+12% +$29.2K ﹤0.01% 2708
2025
Q2 		$202K Buy
17,864
+1,041
+6% +$12.7K ﹤0.01% 2709
2025
Q1 		$195K Buy
16,823
+2,984
+22% +$30.5K ﹤0.01% 2651
2024
Q4 		$118K Buy
13,839
+722
+6% +$7.48K ﹤0.01% 2804
2024
Q3 		$152K Sell
13,117
-12,235
-48% -$154K ﹤0.01% 2742
2024
Q2 		$299K Buy
25,352
+3,210
+14% +$37.5K ﹤0.01% 2412
2024
Q1 		$263K Buy
22,142
+944
+4% +$12.6K ﹤0.01% 2497
2023
Q4 		$260K Buy
21,198
+2,237
+12% +$20.4K ﹤0.01% 2437
2023
Q3 		$183K Sell
18,961
-13,555
-42% -$138K ﹤0.01% 2532
2023
Q2 		$293K Sell
32,516
-4,455
-12% -$41.1K ﹤0.01% 2372
2023
Q1 		$291K Buy
36,971
+92
+0.2% +$686 ﹤0.01% 2355
2022
Q4 		$249K Buy
36,879
+9,933
+37% +$53.2K ﹤0.01% 2448
2022
Q3 		$391K Buy
26,946
+5,947
+28% +$83.1K ﹤0.01% 2252
2022
Q2 		$207K Buy
20,999
+2,672
+15% +$29.5K ﹤0.01% 2588
2022
Q1 		$270K Buy
18,327
+3,666
+25% +$52.7K ﹤0.01% 2589
2021
Q4 		$194K Buy
+14,661
New +$233K ﹤0.01% 2767
2016
Q3 		– Sell
-191,993
Closed -$1.78M – 2543
2016
Q2 		$1.78M Hold
191,993
– – ﹤0.01% 1547
2016
Q1 		$1.73M Buy
191,993
+207
+0.1% +$3.71K ﹤0.01% 1554
2015
Q4 		$9.72M Sell
191,786
-6,757
-3% -$354K ﹤0.01% 1289
2015
Q3 		$9.92M Sell
198,543
-1,693
-0.8% -$144K ﹤0.01% 1307
2015
Q2 		$20M Buy
+200,236
New +$19.9M ﹤0.01% 1139

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates's KALV Position: Q1 2026 in Review

T. Rowe Price Associates increased its KalVista Pharmaceuticals (KALV) stake by 27% in Q1 2026, buying an estimated $101K and bringing the position to 29,367 shares worth $592K. The position accounts for ﹤0.01% of the portfolio, ranked #2373.

T. Rowe Price Associates first reported a position in KALV in Q2 2015 and has held it in 23 quarters since. The position peaked at $20M in Q2 2015. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • T. Rowe Price Associates held 29,367 shares of KalVista Pharmaceuticals worth $592K as of Q1 2026.
  • T. Rowe Price Associates bought 6,249 KalVista Pharmaceuticals shares in Q1 2026, an estimated $101K.
  • KalVista Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2373 holding.
  • T. Rowe Price Associates first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 23 quarters since.
  • T. Rowe Price Associates's KalVista Pharmaceuticals position peaked at $20M in Q2 2015.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.